NasdaqGS:GILDBiotechs
Gilead Sciences (GILD) Valuation Check After Late Stage Oncology Wins And New HIV Prevention Launch
Gilead Sciences (GILD) is back in focus after positive Phase 3 ASCENT-04 data for Trodelvy plus Keytruda in metastatic triple-negative breast cancer, alongside fresh product launches such as the HIV prevention drug Yeztugo.
See our latest analysis for Gilead Sciences.
The recent Phase 3 ASCENT-04 success and the launch of HIV prevention drug Yeztugo sit against a strong backdrop, with a 30 day share price return of 13.29% and a 1 year total shareholder return of 47.96% pointing to building...